Gordhandas, Sushmita B.
Manning-Geist, Beryl
Henson, Christina
Iyer, Gopa
Gardner, Ginger J.
Sonoda, Yukio
Moore, Kathleen N.
Aghajanian, Carol
Chui, M. Herman
Grisham, Rachel N.
Funding for this research was provided by:
National Cancer Institute (P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748)
Article History
Received: 14 October 2021
Accepted: 22 December 2021
First Online: 19 January 2022
Competing interests
: CA reports personal fees from Tesaro, personal fees from Immunogen, grants and personal fees from Clovis, personal fees from Mateon Therapeutics, personal fees from Cerulean Pharma, grants from Genentech, grants from AbbVie, and grants from Astra Zeneca, outside the submitted work. KM reports research funding from Lilly, PTC Therapeutics, Merck, Genentech/Roche, has served on advisory boards for Aravive, Alkemeres, Astra Zeneca, Blueprint pharmaceuticals, Elevar, Eisai, GSK/Tesaro, Genentech/Roche, Immunogen, IMab, INXmed, Lilly, Merck, Mersana, Mereo, Myriad, OncXerna, Oncomed, Tarveda, VBL Therapeutics, serves as associate director for GOG Partners, and is on the Board of Directors for GOG Foundation. MHC served on a medical advisory board on ovarian cancer for Roche, outside the submitted work. RNG reports personal fees from AstraZeneca, Genentech, Springworks, Corcept, and Natera, research funding from Context, and grants from American Society of Clinical Oncology (ASCO), from The Ovarian Cancer Research Fund Alliance, and from Cycle for Survival, outside the submitted work; she reports compensation as an advisory board member for Clovis and Mateon, and serves on a data and safety monitoring board for Regeneron, outside the submitted work. All remaining authors have no conflicts of interest to declare.